Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11821953 | 0.92 | TSHR (0.54) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1483381 | 0.86 | — | — | |
| SCHEMBL21177033 | 0.84 | TSHR (0.61) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL130826 | 0.82 | TSHR (0.64) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL27210237 | 0.81 | TSHR (0.56) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4958389 | 0.80 | TSHR (0.61) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL27274544 | 0.80 | TSHR (0.61) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4178222 | 0.79 | CYP1A2 (0.53) | TSHRALDH1A1L3MBTL1KMT2AMAPT | |
| SCHEMBL3043060 | 0.79 | TSHR (0.54) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL7887199 | 0.79 | TSHR (0.54) | TSHRLMNAALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| WO-2018010932-A1 | CATALYTIC CARBOXYLATION OF ACTIVATED ALKANES AND/OR OLEFINS | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2018-01-18 | — | — | WO | disclosed |
| EP-3269699-A1 | CATALYTIC CARBOXYLATION OF ACTIVATED ALKANES AND/OR OLEFINS | Fundació Institut Català D'investigació Quimica (ES) | 2018-01-17 | — | — | EP | disclosed |
| EP-3269699-A1 | CATALYTIC CARBOXYLATION OF ACTIVATED ALKANES AND/OR OLEFINS | Fundació Institut Català D'investigació Quimica (ES) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017177004-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-0646019-B9 | Biotin-DOTA conjugates and their use in pretargeting methods | NEORX CORP (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-0646019-B1 | Biotin-DOTA conjugates and their use in pretargeting methods | NEORX CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0453966-B1 | Ferroelectric liquid crystal display with high contrast and high brightness | HOECHST AG (DE) | 1997-02-26 | — | — | EP | disclosed |
| US-5384168-A | Multilayer element with electrodes | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-01-24 | — | — | US | disclosed |
| EP-0453966-A2 | Ferroelectric liquid crystal display with high contrast and high brightness | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-30 | — | — | EP | disclosed |
| US-4281010-A | FOR INCREASING BLOOD CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4254269-A | PRECURSERS FOR CARDIOVASCULAR DRUGS | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-03-03 | — | — | US | disclosed |
| US-4206213-A | IMPROVING PERIPHERAL AND CEREBRAL CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-06-03 | — | — | US | disclosed |
| US-4092427-A | ANTICOAGULANTS, OXYTOCICS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-05-30 | — | — | US | disclosed |
| US-4048329-A | HYPERTENSIVE AGENTS, BRONCHODILATOR AGENTS, GASTROINTESTINAL DISORDERS, PROSTAGLANDINS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048328-A | HYPERTENSIVE AGENTS, BRONCHODILATOR AGENTS, GASTROINTESTINAL DISORDERS, PROSTAGLANDINS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4007171-A | PROSTAGLANDIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-02-08 | — | — | US | disclosed |
| US-3987081-A | ALKYL DERIVATIVES OF PROSTANOIC ACIDS AND PREPARATION THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | TSHR 284/4885LMNA 1147/4885ALDH1A1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.